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Theiler's murine encephalomyelitis virus (TMEV)' is a member of the picor-
navirus family. The icosahedral capsid consists of 60 capsomers, each containing
asingle copy ofthefour capsid proteins : VP-1, VP-2, VP-3, andVP-4. Thegenome,
"8,100 nucleotides long, is a single-stranded RNA of positive polarity with more
thana 1,000-base-long 5' noncoding region and a poly(A) tail at theTend (1). Nucleo-
tide sequence analysis has revealed thatTMEV is closely related to the cardioviruses,
i.e ., encephalomyocarditis (EMC) and Mengo viruses (2-4) .
TMEV is a naturally occurring murine virus that leads to an asymptomatic en-
teric infection in most young adult mice . In rare instances, a spontaneous central
nervous system (CNS) disease has been observed (5) . Since its original description
a number of different viral strains have been isolated . The strains can be divided
into two subgroups based on their pathologic and biologic characteristics . TheGD
VII/FA subgroup is highly virulent and produces an acute polio encephalitis that
kills the host . In contrast, members of the TO (Theiler's original) subgroup, which
include the DA strain (6), produce a biphasic disease in susceptible mice (7) . The
acutedisease is similar tohuman poliomyelitis and is characterized by virus replica-
tion, inflammation, necrosis of neurons, and glial cell proliferation (8) . Survivors
of the acute phase go on to develop the secondary chronic disease that is marked
by spasticity of limbs (7) . The relative severity of the acute versus chronic disease
is dependent on the genetic background ofthe mice (9) . In SJL/J mice, most of the
infected animals survive the acute disease without exhibiting severe clinical symp-
toms (7).
The pathological features of the chronic disease include extensive meningeal and
perivascular infiltrates with concomitant demyelination (10) . Thecellular infiltrates
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in the CNS are comprised of macrophages, lymphocytes, monocytes, and plasma
cells (8). During the chronicstage ofthediseasemost pathologic processes arelimited
to the CNS (11). The demyelination parallels incomplete CNS-type remyelination
by oligodendrocytes (10, 12).
The mechanisms by which TMEV infection of the CNS induces demyelination
are still notfully understood. Persistent infection ofthe CNS (13, 14)and thedemon-
stration of viral RNA and antigen in oligodendrocytes during the chronic disease
(15, 16) and demyelination in athymic nude mice (17, 18) support direct viral effects
that can lead to demyelination. Other observations suggest that immune-mediated
mechanisms are responsible ,for demyelination (19-24).
The complete nucleotide sequences of members of both TMEV subgroups (GD-
VII vs. TO) have been determined (1, 3, 4), and infectious cDNA of representative
strains of each subgroup have been prepared (25) (Roos, R. P, personal communi-
cation). It should now be possible to use a combination of sequence comparison
and construction of recombinants between the strains to identify specific sequences
that are responsible for the differences in pathogenesis in TMEV.
This approach has been successful in identifying sequences responsible for attenu-
ation in the Sabin attenuated vaccine strains of poliovirus . Comparisons between
the Sabin strain of type 3 poliovirus, its neurovirulent parent Leon, and a neoviru-
lent revertantisolated from a fatal vaccine associated case of poliomyelitis, suggested
that a substitution at position 472 in the 5' noncoding region of the genome was
an important determinant of attenuation in the P3/Sabin strain (26). Subsequent
construction of genetic recombinants between the P3/Sabin and P3/Leon strains
confirmed that the substitution at position 472 was an important marker ofattenua-
tion and identified a second attenuating mutation, a mutation resulting in the sub-
stitution of phenylalanine (Sabin) for serine (Leon) at amino acid 91 of the capsid
proteinVP-3 (27). Recombinants have also been used to show that mutations within
the 5' noncodingregion ofthe Sabin strain oftype 1 poliovirus contribute significantly
to its attenuation and that a single 10-residue stretch of amino acids in the capsid
proteinVP-1 is an important determinant ofhost range in themouseadapted Lansing
strain of type 2 poliovirus (21, 28).
Although the use of sequence comparisons and genetic recombinants is expected
to be valuable in identifying general regions of the genome responsible for differ-
ences in pathogenicity of Theiler's virus, the large number of sequence differences
betweennaturally occurringstrainspresents asignificant obstacle in identifying specific
sequence differences that areresponsible fordifferences in phenotype. We have, there-
fore, used an alternative approach, namely the characterization of variants with al-
tered pathogenicity. mAbs have been used to select for variants of reovirus (29) and
mouse hepatitis virus (30, 31) that were shown to be attenuated. Previously, we de-
scribed an altered and diminished pattern of diseaese in immunocompetent SJL/J
mice infected with such avariant virus(32). This variantvirus (H7A6-2) wasselected
with a neutralizing mAb H7. The variant was shown to initiate less inflammatory
lesions in the spinal cord and was cleared from the CNS. The observed changes in
the pattern of disease may reflect how the immune system interacts with this deter-
minant in the context of virus infection. Alternatively, modifications to structural
proteins may effect the ability of the variant virus to infect oligodendrocytes and
produce inflammation and concomitant demyelination.ZURBRIGGEN ET AL.
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In this report we have characterized the variant by investigating its ability to be
bound and neutralized by mAbs as well as by sequencing selected regions of the
RNA genome. These studies demonstrate that the variant contains an alteration
in a neutralizing epitope located in the capsid protein VP-1, and suggest that a single
point mutation at amino acid 101 of VP-1 is responsible for the attenuation of the
variant. Model building based on sequence alignments and the known structure of
the related Mengo virus (33) shows that the altered amino acid is located in an ex-
posed loop on the surface of the virus at the periphery of a site that has been pro-
posed to be the receptor binding site. Thus, the results of this study provide for the
first time an opportunity to precisely map an important structural determinant of
virally induced demyelination.
Materials and Methods
Cells.
￿
BHK-21 cells were cultured in DME (Cell Culture Facility, University ofCalifornia,
San Diego, CA), supplemented with 10% FCS (HyClone Laboratories, Logan, UT), nones-
sential amino acids, glutamine, sodium pyruvate, penicillin, streptomycin, and amphotericin
B (Irvine Scientific, Santa Ana, CA). Cells were passaged twice weekly. BHK-21 cells were
kindly provided by Drs. Don Summers and Ellie Ehrenfeld at the University of Utah, Salt
Lake City, UT.
ELISA andAntibody (mAb).
￿
The ELISA was performed as described earlier by Rice and
Fujinami (34). For viralantigen, cytoplasmic extracts from cells infected with either GDVII,
the H7A6-2 variant, or the parental DA viruses were used. In this study the mAbs used were
mAb H5, a nonneutralizing antibody, and two neutralizing antibodies mAb H7, used to se-
lect the variant virus and mAb H8. All three mAbs recognize VP-1 of the DA strain by Western
immunoblots and have been characterized in detail (35).
Virusand Variant VirusSelection.
￿
The DA strain ofTMEV used in this study as the parental
strain was originallyobtained fromJ. Lehrich and B. Amason (36). Passage history and variant
virus selection have been previously described (32). Briefly, DA virus was incubated with
neutralizing mAb to VP-1 for 1 h and then plaqued on BHK-21 cell monolayers. Plaques
were picked and the procedure was repeated a total of three times. Variant viruses that "es-
caped" neutralization were additionally plaque purified and a stock of these variants was pre-
paredin BHK-21 cells. A variant virus (H7A6-2), which showed a markedly reduced pathoge-
nicity (32), was used for sequence analysis, as well as the parental DA virus.
The GDVII virus strain used for antibody studies was purchased from American Type
Tissue Collection (Rockville, MD) and was propagated similarly as the DA strain in BHK-21
cells. Antigen from this highly virulent strain was also used for ELISA (34).
Neutralization Assay.
￿
Approximately 200 plaque forming units (PFU) of variant virus
(H7A6-2), parental DA, or GDVII viruses in 100 i,1 were incubated with various dilutions
of mAbs H5, H7, or H8 in 10 p,l for 1 h on ice. The nonneutralizing mAb H5 served as
a negative control. The virus-antibody solution was allowed to adsorb onto BHK-21 cell
monolayersfor 1.5 h at room temperature. The cell monolayerswere overlaid with 0.5% agarose
in medium 199 (Gibco Laboratories, Grand Island, NY), and incubated for 4 d at 370C.
After fixation and staining with lo7o crystal violet, plaques were enumerated (37).
Polyacrylamide GelElectrophoresis (PAGE).
￿
BHK-21 cells infected with the variant virus or
the DA virus were harvested and processed for virus purification asdescribed (35). The purified
virus pellets were resuspended in SDS-sample preparation buffer (38) and analyzed on 14%
polyacrylamide protein gels.
Reparation ofInfected Cellular RNA Templates.
￿
Total cellular RNA was prepared from 3 x
108 suspension BHK-21 cells, grown in 150-cm2 culture flasks (Costar, Cambridge, MA).
These cellsinfected with either parental DA or with variant viruses were harvested 22 h after
infection. Under these conditions both virses grew to similar titers as judged by previous
plaquing studies. After washing with PBS the infected cells were resuspended in 1 ml of 25
mM sodium citrate pH 7.0 (Fisher Scientific, Pittsburgh, PA). The cells were then lysed by2040
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the addition of 8 ml ofGTC solution (4 M guanidinium thiocyanate from International Bio-
technologies, New Haven, CT; 25 mM sodium citrate, 0.5% sodium lauryl sarcosine from
Sigma Chemical Co., St. Louis, MO; 0.1 mM 2-ME from Fisher Scientific) and the DNA
was sheared by vortexing. The lysate was then overlaid onto a 2 ml 5.7 M cesium chloride
(Sigma Chemical Co.) cushion, and then centrifuged at 30,000 rpm in an SW41 rotor(Beckman
Instruments, Fullerton, CA) at 15°C for 20 h. The resulting RNA pellet was dissolved in
diethylpyrocarbonate (Behring Diagnostics, LaJolla, CA)-treated water and phenol/chloro-
form was extracted.
Oligonuckodde P~irners.
￿
Selected oligonucleotide primers complementary to different regions
of the published DA virus sequence (1) were synthesized on a gene assembler (Pharmacia
Fine Chemicals, Uppsala, Sweden). After purification on a 16% sequencing gel, 50 pmol
of oligonucleotides were endlabeled with y-[32P]ATP (Amersham Corp., Arlington Heights,
IL) using T4-polynucleotide kinase (Boehringer Mannheim Biochemicals, Indianapolis, IN)
in 50 mM Tris pH 7.5, 10 mM MgC12, 5 mM dithiothreitol (DTT) (Sigma Chemical Co.),
0.1 mM spermidine, and 0.1 mM EDTA (Sigma Chemical Co.).
RNA Sequencing.
￿
A dideoxynucleotide RNA sequencing technique previously described
(39) was used. Basically, 5 ng of 32P-labeled oligonucleotide primer were mixed with 10 jug
RNA in a totalof 12 IAl annealing buffer (50 mM Tris, pH 8.3, 60 mM NaCl, 10 mM DTT,
and 1 mM EDTA). After heating at 90°C for 3 min the oligonucleotides were annealed to
the RNA at 45 °C for 30 min. Four reactions were carried out in wells of a 96-well plate la-
beled T, C, G, and A. To each well, 2 ul sequencing reaction mix (80 mM Tris pH 8.3, 100
mM NaCl, 15 mM DTT, 10 mM MgAc2, 1 mM ofeach dNTP and 0.1 mM ofeither ddTTP,
or ddCTP, or ddGTP, or ddATP; Pharmacia LKB Biotechnology, Piscataway, NJ), 2 kl of
the annealed oligonucleotide-RNA solution, 2 pl diluted AMV reverse transcriptase (3 U/well,
Boehringer Mannheim Biochemicals) were added. The reaction was carried out at 45°C for
30 min followed by the addition of 2 pl of a chase solution (0.25 mM of each dNTP, 0.15
M KCI, 50 mM Tris pH 8.3, 10 mM MgC12) and incubated for 15 min. The reaction was
stopped with 4 pl formamide dye buffer (0.1% xylene cyanol, 0.1% bromophenol blue, 0.37
EDTA in deionized formamide; J. T. Baker Chemical Co., Phillipsburg, NJ). After boiling
for 5 min the samples from the variant virus and parental DA virus were loaded in separate
lanes onto a 6% acrylamide, 8 M urea sequencing gel and separated at 40 W for 1.5 h (39).
After autoradiography the DNA sequence complementary to the viral RNA sequence from
the variant virus, the parental DA virus and the earlier published DA virus sequence (1) were
compared. In some instances formamide gels were used to unambiguously ascertain regions
where stops and/or compressions were not fully resolved by the conventional gels. Briefly,
6% acrylamide, 8 M urea, and 40% deionized formamide sequencing gel were run at 40
W for 2.5 h (40). After drying the gels were processed for autoradiography.
Results
In a previous report we described a TMEV variant (H7A6-2) resistant to neutral-
ization by a mAb, H7 (32). After infection of mice with this variant virus an altered
and diminished disease pattern compared with the parental DA wild-type strain was
observed. The variant virus produced significantly less inflammatory lesions and
smaller numbers of infected cells were demonstrated with immunohistochemistry.
The number of infected cells in the wild-type mice steadily increased, whereas the
virus-positive cells from the variant mice gradually decreased after 1 wk after infec-
tion. Variant virus was cleared from the CNS, whereas wild-type virus persisted in
the spinal cord. This variant virus was selected with a neutralizing mAb to VP-1.
In this report we defined the exact sequence difference in VP-1 between the variant
and parental DA virus, which is apparently responsible for neutralization escape
and altered pathogenesis.
ELISA.
￿
The ability of several mAbs to bind the variant, the parental DA strain,
and the neurovirulent GDVII strain were examined by ELISA. ELISAs were per-ZURBRIGGEN ET AL.
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formed using two different neutralizing mAbs, H7 and H8, and a nonneutralizing
mAb H5, which all have been shown to be directed to the capsid protein VP-1 (35).
Cytoplasmic extracts prepared from BHK-21 cells infected with GDVII (virulent),
DA (TO type), or the variant H7A6-2 viruses served as antigens. mAb H5 bound
to all three tested virus strains. By ELISA mAb H8 had a relative titer of 13.4 to
DA virus, 13.4 to GDVII virus, and 14.9 to H7A6-2 viral antigen (Table I). Thus
mAb H8 reacted with all three viral strains. mAb H7, which was used to select the
neutralization resistant variant H7A6-2, reacted only with viral antigen prepared
from cells infected with the wild-type DA virus strain. mAb H7 bound neither to
GDVII nor to H7A6-2 virus variant. More over, mAb H7 does not recognize the
BeAn strain ofTMEV(Pevear, D. C., and H. L. Lipton, personalcommunication).
These data indicate that mAb H7 recognizes a different epitope than mAb H8 and
H5 and that epitopes recognized by H8 and H5 are unchanged in the variant. Fur-
thermore, the results demonstrate that the variant virus H7A6-2 has been changed
at an epitope in which GDVII and BeAn virus differ from the wild type DA virus
strain.
Neutralization Assay.
￿
The ELISA results indicateddifferences in thevarious mAbs
abilityto bind tovarious strains. To determinewhetherthe change inthe H7 binding
epitope altered the ability ofthe mAbs to neutralize variant virus, versus parental
DAand GDVIIviruses, neutralization assays were conducted. Bindingofantibody
does not necessarily reflect its ability to neutralize infectivity, mAb H7 neutralized
only DA virus (Table II). mAb H5, the negative control that has the ability to bind
to DA virus asdetermined by ELISA didnotneutralize any ofthe three virus strains.
TABLE I
ELISA Reactivity: Lack of Binding of mAb H7 to Variant or GD-VII
The ELISA was performed using mAb H5, H7, and H8 and cytoplasmic ex-
tracts from cells infected with either the parental DA, the GD-VII, or the vari-
ant H7A6-2 for viral antigen.
Relative titer in loge
TABLE II
Lack of mAb H7 to Neutralize Variant or GD-VII
Neutralization assays were performed with '200 PFU of either parental DA,
GD-VII, or variant H7A6-2 virus and various dilutions of mAbs H5, H7, or
H8. Neutralization was scored as + when all infectivity was eliminated.
' At a dilution o£ 1/1,000 and comparable levels of immunoglobulins in H5,
H7, and H8.
Virus antigen H5
mAb'
H7 H8
DA 14 21 .7 13.4
H7A6-2 15.4 2.2 14.9
GD-VII 16.3 0 13.4
Virus antigen H5
mAb'
H7 H8
DA - + +
H7A6-2 - - +
GD-VII - - +2042
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mAb H8 neutralized all three viruses, DA, GDVII, and H7A6-2, indicating that
mAb H8 and H7 define two differentneutralizing epitopes within VP-1. In contrast
to the epitope recognized by mAb H7 that appears to be highly specific for the DA
strain, the epitope recognized by mAb H8 appears to be conserved in virus strains
with grossly altered pathogenicity and is therefore unlikely to represent an area on
the virion surface which is important for pathogenesis.
Migrational Characteristics.
￿
To determineifaportion ofVP-1 from the variantvirus
H7A6-2 was deleted such as with coronaviruses (Parker, S., and M. J. Buchmeier,
manuscript in preparation) or majorchangesin the migrationalcharacteristicscould
be observed, the viral capsid proteins were analyzed by PAGE. No demonstrable
differences in the migrationof the capsid proteins, VP-1, VP-2, VP-3 and VP-4 were
observed between DA and H7A6-2 virus (datanot shown). Thus, there wasno major
deletion in the H7A6-2 variant virus proteins, particularly VP-1. These data sup-
port the antibody binding and neutralization studies (above) where major changes
in binding were not observed i.e., changes at one site did not affect other sites.
RNA Sequencing.
￿
To precisely define the mutation(s) in the H7A6-2 variant, we
sequenced selected regions of the viral RNA. Because ELISA and neutralization
analysis demonstrated that mAb H7 binds to the wild-type DA strain but not to
the H7A6-2 variant and recognizes VP-1 of the DA strain by Western blots, the en-
tire coding region for VP-1 was sequenced. Two additional regions including 110
nucleotides in the 5' noncoding region of the genome, and 105 nucleotides in the
region of the genome encoding the capsid protein VP-2 were sequenced. Taken to-
gether the three regions sequenced account for N15% of the total viral genome. Be-
cause our parental wild-type strain and the DA strain sequenced by Ohara et al.
(1) have undergone multiple independent passages, we also determined the corre-
sponding sequences in our wild-type strain.
Theparental DA strain was shownto differ from the sequence published by Ohara
et al. (1) at five nucleotide positions (Table III). Two of the sequence changes (the
replacement of a cytosine by a guanine at nucleotide 3429 and the replacement of
a cytosine by a thymine at nucleotide 3666) were silent. The remainingthree substi-
tutions resulted in the change ofa serine to athreonine at amino acid 2 of the capsid
proteinVP-1 and the change of a leucine to a tryptophan at amino acid 214ofVP-1 .
Since the two wild-type DA strains cause a similar disease in SJL/J mice, it is un-
likely that these changes are relevant to the pathogenesis of Theiler's virus.
TABLE III
Sequence Comparisons between Two DA Wild-type Strains
Nucleotide and resulting amino acid substitutions within VP-1 ofthe published
DA (DA") virus versus our parental DA strain .
' Previously published DA sequence (1).
Nucleotide change Amino acid change
Position DA" Our DA Position DA' Our DA
3008 G C Ser Thr 2
3009 C G
3429 C G Silent
3644 T G 214 Leu Trp
3666 C T SilentZURBRIGGEN ET AL.
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Comparisons of the sequence in the region of the genome encoding VP-1 in the
parental DA virusstrain and the variant virus H7A6-2 showed only one single nucleo-
tide difference at position 3305 (Table IV). In addition these data explain why mAb
H7 does not react with BeAn or GDVII (Table I). At this position a cytosine was
replaced by a thymine (Fig. 1, resulting in the replacement of a threonine (wild-
type) by an isoleucine (variant) at amino acid 101 of VP-1. Alignment of the DA
virus VP-1 sequence with the atomic structure of Mengo virus (33) localized this
amino acid modification in the second loop connecting the B and C strands of the
0 barrel of VP-1 (Fig. 2, leftpaneo. Model building studies based on sequence align-
ments and the known structure of Mengo virus suggest that this loop is highly ex-
posed on the surface ofthe virion (Fig. 2, rightpaneo, and previous studies by others
(41) have identified this loop as a potential antigenic site in the BeAn Strain ofTMEV.
The location of the amino acid substitution on the virion surface, together with
the observation that mAb H7 binds VP-1 in Western blots (35) for wild-type but
not variant virus, strongly suggests that this mutation is responsible for neutraliza-
tion escape. Because the mutation was selected underconditions that favor selection
of single point mutations, it is also likely that this mutation is responsible for the
previously characterized alteration in the ability of the variant to cause the chronic
demyelinatingdisease. However, in orderto investigate thepossibility that additional
mutations contribute to neutralization escape or attenuation of demyelinatinn, two
additional regions of the genome were sequenced. The first region encodes amino
acids 140-175 of the capsid protein VP-2. Model building based on sequence align-
ments and the known structure of Mengo virus suggested that these amino acids
constitute theloop connecting the Dand E strand ofthe(3 barrel ofVP-2. Moreover,
the modeling suggests that in the virion this loop is sufficienty close to theC-D loop
of VP-1 (including amino acid 101) to constitute aportion of a single antigenic site.
The second area, nucleotides 410-520 in the 5' noncoding region of the genome,
was selected because previous studies (26) had shown that mutations in the 5' non-
coding region were important determinants of attenuation in poliovirus. In both
TABLE IV
Sequence Comparisons Among Different TMEV Strains Beginning at
Nucleotide 3295 of the DA Virus
Comparison of different TMEV sequences encoding the area with the point mutation in
the H7A6-2 variant.
" Published sequence (1).
I Sequence of our DA strain.
DA1' TCC GGC GGT ACC ACC AAT TTT CCA
S G G T T N F P
DA21 TCC GGC GGT ACC ACC AAT TTT CCA
S G G T T N F P
H7A6-2 TCC GGC GGT ATC ACC AAT TTT CCA
S G G I T N F P
BeAn TCT GGC GGC GTC AAC GGT GCC AAC TTT CCG
S G G V N G A N F P
GD-VII TCT GGT GGC GCC AAT GGT GCC AAC TTC CCA
S G G A N G A N F P2044
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FIGURE 1 . Sequence comparisons be-
tween the parentalDA strain andthe H7
variant showed only one single nucleotide
difference at position 3305 (") . Acytosine
(DA) was replaced by thymine (H7). The
H8 variant showed no nucleotide differ-
ences at this area.
FIGURE 2 .
￿
Alignment of the variant virus VP-1 sequence with the atomic structure of Mengo
virus localized the modified amino acid on loop II of VP-1 (left) indicates that this loop is highly
exposed on the surface of the virion (right) .ZURBRIGGEN ET AL.
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of these regions the sequence of the H7A6-2 variant was identical to that of the pa-
rental DA strain.
Discussion
A variant virus of the DATMEV strain was selected by a neutralizing mAb. In-
fection of SJL mice with variant virus or parental wild-type virus resulted in major
differences regarding size and number of inflammatory lesions and number of in-
fected cellsfound in the CNS. The variant virus was less virulent than the wild-type
virus and produced a markedly diminished disease (32). The purpose for this study
was to molecularly define the precise mutation in the variant that is responsible for
neutralization escape and attenuation by sequencing selected regions of the viral
genome. Since the selectingmAb bound VP-1 from thewild-type but does not bind
to the H7A6-2 variant at all, we focussed our sequencing efforts on the region of
the genome coding for the capsid protein, VP-1. Two additional regions were se-
quenced, including the coding sequences fora region of VP-2, which has been pro-
posed to be a component of a neutralizing epitope of Theiler's virus (41) and a por-
tion of the 5' noncoding region of the genome.
The variant was isolated under conditions that favorthe selection of single point
mutations. The variant and parental DA strains grow to similartiters and with very
similar kinetics and titers in cell culture and in the brain early in infection (32),
making it unlikely that the variant has an additional fortuitous mutation that affects
its ability to replicate. Thus, the data suggest that the observed mutation is respon-
sible for the attenuation of the demyelinating diseasein the variant. Infectious tran-
scripts ofGDVII (25) and ofthe DA strain (Roos, R. P, personal communication)
have been constructed. They will allow genetic manipulations, e.g., single nucleo-
tide replacements and evaluation of these changes on pathogenesis.
Theparental DA strain used in thesestudies has been propagated separately from
the DA strain sequencedby Oharaet al. (1) forat least 10 yr. Therefore, it was neces-
sary to sequence our parental strain in parallel with the variant. Sequence compar-
isons between our DA strain and a published DA sequence (1) revealed five nucleo-
tide differences. This lead to twoamino acid changes within VP-1 and one nucleotide
difference within the 5' noncoding region. Even though these nucleotide differences
exist between the DA virus of Roos and colleagues (17) and ourDA wild-type virus
(18) both DA viruses produce a similar disease. In contrast, the disease induced by
variant virus H7A6-2 differs markedly from the pathology caused by the parental
DA virus strain. The observed nucleotide differences in sequence between these two
wild-type DA strains may be attributed to the high frequency of mutations within
picornaviruses (42). Alternatively, at least some of the sequence differences may be
ascribed to differences in sequencing techniques. Ohara et al. (1) used complimen-
tary DNA as a template for their sequencing experiments. Ourfindings were gener-
ated from sequence analysis using viral RNA as templates. In both methods, the
ability to sequence is dependent on transcription enzymes that have been shown
to be error prone.
Comparison ofthe sequences of the H7A6-2 variant and our parental DA strain
revealed only one nucleotide difference within the analyzed regions, namely, the
substition of a thymine (inthe variant) in placeofcytosine (in the parent) at nucleo-
tide 3305 (Fig. 1). This single nucleotide change led to a change in amino acid 1012046
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ofVP-1 in which threonine (in the parent) was replaced by an isoleucine (in the
variant). No changes were found near the COOH-terminal trypsin cleavage site of
VP-1, closetoanotherneutralizing epitope (1), norwere there any sequence changes
in the two other regions of the genome that were sequenced. Since this mutation
is the only mutation found in VP-1, and since the mutation results in the loss of
the ability ofthe selecting mAb H7 to bind to the variant virus, it is clear that this
single mutation is responsible for neutralization escape. Consistent with the results
ofthe binding andneutralization assays that showthat the selecting mAb H7 recog-
nizes only the parental DA strain, the mutation in the variant is located in a region
ofsignificant divergence in the known Theiler's virus sequences. Indeed, in addition
to substantial sequence differences theGDVII and BeAn strains contain two addi-
tional amino acids within this loop containing the mutation (Table IV).
The modified amino acid is located in the second oftwo loops connecting the C
and Dstrands ofthe /3 barrel ofVP-1. This loop(called loop II in the nonmenclature
ofLuo) (33) is highly exposed on the surface of the virion in a region previously
identified as a potential neutralizing epitope in Theiler's virus (41). The loop is on
the periphery of a deep depression (or "pit") in the surface ofthe virion that has
been proposed asaprobable receptorbinding site in Mengo virus(33)andin Theiler's
virus (41). This loop II region containing the observed amino acid difference in the
variant virus H7A6-2 is ofgeneral importance for picornaviruses. In recombinant
studies the same area determines the host range for poliovirus type 2 (28) and is
important forneurovirulence ofthe Lansingstrain type 2 in mice (21). Additionally,
this structure in poliovirus types 1, 2, and 3 has been identified to contain a major
neutralizingepitope (43). Peptides representingaminoacids 90-104 ofVP-1 inhibited
neutralization ofpoliovirustype I by a neutralizingmAb. Antigenic poliovirustype
3 mutants resistant to neutralization by different mAbs had single point mutations
clustered within this area (44, 45). The location of the mutation in the variant is
consistent either with a mechanism in which the mutation alters the immune re-
sponse to the virus in such a way that the variant is more efficiently cleared, orwith
a mechanism in which the mutation alters the ability to bind or infect the target
cells for persistent infection (oligodendrocytes?) in the CNS. The question ofhow
a mutation that destroys a neutralizing epitope in vitro causes an enhanced clear-
ance in vivo, leads us to favor the second mechanism (alteration of cell tropism).
Indeed, asimilar mechanismhas been usedtoexplain theobservationthat sequence
alterations in an exposed loop of VP-1 alter host range in poliovirus (21, 28).
This is the firstdemonstrationofthe epitopebeing importantin the TMEV patho-
genesis. The epitope was defined by ELISAs and neutralization assays using mAbs
and the exact sequence of the epitope was determined. We describe here a single
point mutation within the structural capsid proteinVP-1, which alters the pathoge-
nicity of the variant virus. The modified amino acid on loop II ofVP-1 is part of
a neutralizing epitope as determined by neutralization assays. This epitope has an
important in vivo function in determining pathogenesis and neurovirulence.
Summary
Chronic Theiler's murine encephalomyelitis virus infection of susceptible mice
is an animal model forhuman demyelinating diseases. Previously we described an
altered and diminished patternofcentral nervous system disease in immunocompe-tent SJL/J mice infected with a variant virus (32). This variant virus H7A6-2 was
selected with a neutralizing mAb recognizing the capsid protein VP-1 of Theiler's
virus. Here we characterize the variant virus by ELISA and neutralization assays
and by sequencing selected regions of the viral RNA genome and relate the altera-
tion to disease. The variant virus contains one single point mutation within a neu-
tralizing epitope of VP-1. This nucleotide change lead to an amino acid replacement
at amino acid 101 ofVP-1, a threonine (wild type) to an isoleucine (variant). Model
building based on sequence alignments and the known structure ofthe related Mengo
virus (33) indicates that the altered amino acid is located in an exposed loop on the
surface ofthe virus at the periphery ofa site that has been proposed to be the receptor
binding site. The results of ELISA, neutralization assay, and direct RNA sequencing
provide for the first time an opportunity to precisely map an important structural
determinant of neurovirulence.
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